DE69133120T2 - GMP-140 Ligand - Google Patents

GMP-140 Ligand

Info

Publication number
DE69133120T2
DE69133120T2 DE69133120T DE69133120T DE69133120T2 DE 69133120 T2 DE69133120 T2 DE 69133120T2 DE 69133120 T DE69133120 T DE 69133120T DE 69133120 T DE69133120 T DE 69133120T DE 69133120 T2 DE69133120 T2 DE 69133120T2
Authority
DE
Germany
Prior art keywords
gmp
alpha
sialyated
carbohydrate
structures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69133120T
Other languages
English (en)
Other versions
DE69133120D1 (de
Inventor
Rodger P Mcever
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Original Assignee
University of Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oklahoma filed Critical University of Oklahoma
Application granted granted Critical
Publication of DE69133120D1 publication Critical patent/DE69133120D1/de
Publication of DE69133120T2 publication Critical patent/DE69133120T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69133120T 1990-07-17 1991-07-17 GMP-140 Ligand Expired - Fee Related DE69133120T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55419990A 1990-07-17 1990-07-17
US65048491A 1991-02-05 1991-02-05

Publications (2)

Publication Number Publication Date
DE69133120D1 DE69133120D1 (de) 2002-10-31
DE69133120T2 true DE69133120T2 (de) 2003-05-15

Family

ID=27070521

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133120T Expired - Fee Related DE69133120T2 (de) 1990-07-17 1991-07-17 GMP-140 Ligand

Country Status (9)

Country Link
EP (2) EP0714912B1 (de)
JP (5) JP3096305B2 (de)
AT (1) ATE224911T1 (de)
AU (2) AU660627B2 (de)
CA (1) CA2086323C (de)
DE (1) DE69133120T2 (de)
DK (1) DK0714912T3 (de)
ES (1) ES2183851T3 (de)
WO (1) WO1992001718A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800815A (en) * 1903-05-05 1998-09-01 Cytel Corporation Antibodies to P-selectin and their uses
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
ES2097765T3 (es) * 1989-10-20 1997-04-16 New England Medical Center Inc Un sistema de inhibicion del enlazado de celulas intermediado por padgem.
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
NZ240316A (en) * 1990-10-25 1996-12-20 Univ Michigan Compound for treating disease mediated by the elaboration of elam-1 on endothelial cells
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
ATE338762T1 (de) * 1991-04-19 2006-09-15 Univ Leland Stanford Junior Zusammensetzungen und methoden für die verknüpfung von endothelzellen
US6121233A (en) * 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
JPH06507639A (ja) * 1991-05-03 1994-09-01 ザ ロックフェラー ユニバーシティ セレクチンとｂ百日咳毒素の間のアミノ酸シーケンスの相同性−それから誘導されるペプチド、それに対する抗体、薬剤組成物
WO1992020708A1 (en) * 1991-05-14 1992-11-26 Board Of Regents For The University Of Oklahoma Peptide inhibitors of inflammation
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
EP0608260A1 (de) * 1991-09-10 1994-08-03 Centocor, Inc. Von selectinen abgeleitete peptide zur behandlung von entzündungen
WO1993005803A1 (en) * 1991-09-25 1993-04-01 Genetics Institute, Inc. Anti-inflammatory selectin inhibitors
EP0602194A1 (de) * 1991-12-18 1994-06-22 Centocor, Inc. Peptid-inhibitoren von die durch selektine verursachten entzundungen
PT639224E (pt) * 1992-04-30 2000-12-29 Genentech Inc Variantes do dominio de lectina da selectina
US6033667A (en) * 1992-05-05 2000-03-07 Cytel Corporation Method for detecting the presence of P-selectin
DE69332881T2 (de) * 1992-05-05 2004-01-29 Aeres Biomedical Ltd Antikörper gegen p-selectin und ihre verwendung
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
JPH08504171A (ja) * 1992-05-28 1996-05-07 セントコー・インコーポレーテッド セレクチン結合のペプチド阻害剤
WO1993024526A1 (en) * 1992-05-28 1993-12-09 Centocor, Inc. Peptide inhibitors of selectin binding
US5440015A (en) * 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
EP0664711A1 (de) * 1992-09-08 1995-08-02 Centocor Inc. Peptid-inhibitoren gegen die zelluläre adhäsion
JPH08501569A (ja) 1992-10-02 1996-02-20 アルバータ リサーチ カウンスル 糖質結合ペプチドの抗炎症性、免疫寛容原性、および免疫阻害性
ATE256182T1 (de) * 1992-10-23 2003-12-15 Inst Genetics Llc Neuartiges p- selectin ligandenprotein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
AU681369B2 (en) * 1992-11-16 1997-08-28 Board Of Regents Of The University Of Oklahoma, The Glycoprotein ligand for P-selectin and methods of use thereof
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
US5856300A (en) * 1994-05-12 1999-01-05 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
DK0730608T3 (da) 1993-05-17 2002-07-22 Avant Immunotherapeutics Inc Præparater omfattende komplementrelaterede proteiner og carbohydrater og fremgangsmåder til fremstilling og anvendelse af præparaterne
US5976540A (en) * 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
CA2142153A1 (en) * 1994-03-04 1995-09-05 Jacques Banville Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
US5663151A (en) * 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
AU2361395A (en) * 1994-04-28 1995-11-29 Genetics Institute Inc. Novel P-selectin ligand protein
US5686426A (en) * 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
EP0833650A4 (de) * 1995-06-14 2005-01-19 Gen Hospital Corp P-selectin-ligenden und verwandte molekule sowie methoden
US5747463A (en) * 1995-11-13 1998-05-05 Bristol-Myers Squibb Company Malonate derivatives of glycolipids as cell adhesion inhibitors
ES2281914T3 (es) 1996-06-10 2007-10-01 Thomas Boren Antigeno del grupo de union a adhesina de helicobacter pylori.
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
EP1773400A2 (de) 2004-07-08 2007-04-18 Amgen Inc. Therapeutische peptide
EP1797127B1 (de) 2004-09-24 2017-06-14 Amgen Inc. Modifizierte fc-moleküle
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP5209476B2 (ja) 2005-09-02 2013-06-12 グリコミメティクス， インコーポレイテッド ヘテロ二官能性全セレクチン阻害剤
US8895510B2 (en) 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
ES2655443T7 (es) 2011-12-22 2021-03-22 Glycomimetics Inc Compuestos antagonistas de E-selectina
CA2891514C (en) 2012-12-07 2020-08-25 Glycomimetics, Inc. Compounds, compositions and methods using e-selectin antagonists for mobilization of hematopoietic cells
CN107108679B (zh) 2014-12-03 2020-10-23 糖模拟物有限公司 E-选择蛋白和cxcr4趋化因子受体的异双官能抑制剂
CA3009836A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
JP7069136B2 (ja) 2016-10-07 2022-05-17 グリコミメティクス， インコーポレイテッド 極めて強力な多量体ｅ－セレクチンアンタゴニスト
KR102630011B1 (ko) 2017-01-11 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
JP7211961B2 (ja) 2017-03-14 2023-01-24 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
JP7272956B2 (ja) 2017-03-15 2023-05-12 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
AU2019230013A1 (en) 2018-03-05 2020-09-10 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4629784A (en) 1983-08-16 1986-12-16 The University Of Georgia Research Foundation, Inc. Synthesis of cyclopropane amino acids
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4783330A (en) * 1984-11-15 1988-11-08 New England Medical Center Hospitals, Inc. Monoclonal antibodies to activated platelets
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5030723A (en) * 1988-05-31 1991-07-09 The Biomembrane Institute Long-chain glycolipid structure
ES2097765T3 (es) * 1989-10-20 1997-04-16 New England Medical Center Inc Un sistema de inhibicion del enlazado de celulas intermediado por padgem.

Also Published As

Publication number Publication date
CA2086323C (en) 2002-05-14
EP0544815A1 (de) 1993-06-09
JPH11147900A (ja) 1999-06-02
EP0714912B1 (de) 2002-09-25
EP0714912A3 (de) 1996-06-26
JP2004002444A (ja) 2004-01-08
WO1992001718A3 (en) 1992-05-14
AU660627B2 (en) 1995-07-06
ATE224911T1 (de) 2002-10-15
DE69133120D1 (de) 2002-10-31
EP0714912A2 (de) 1996-06-05
CA2086323A1 (en) 1992-01-18
JP3096305B2 (ja) 2000-10-10
ES2183851T3 (es) 2003-04-01
JPH05509330A (ja) 1993-12-22
DK0714912T3 (da) 2003-02-03
JP2005255691A (ja) 2005-09-22
AU697488B2 (en) 1998-10-08
WO1992001718A2 (en) 1992-02-06
AU1773195A (en) 1995-07-06
AU8620791A (en) 1992-02-18
JP2001197899A (ja) 2001-07-24

Similar Documents

Publication Publication Date Title
ATE224911T1 (de) Gmp-140 ligand
Spiro et al. Structure of the O-glycosidically linked carbohydrate units of fetuin
Cantoni et al. p49, a putative HLA class I‐specific inhibitory NK receptor belonging to the immunoglobulin superfamily
Gabius Animal lectins
Kobata Structures and functions of the sugar chains of glycoproteins
Chung et al. Properties of a basement membrane-related glycoprotein synthesized in culture by a mouse embryonal carcinoma-derived cell line
Powell et al. Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2, 6-linked sialic acids that are required for recognition.
CA2351637A1 (en) Recombinant glycoproteins, method for the production thereof, medicaments containing said glycoproteins and use thereof
Foltz et al. Purification and characterization of an extracellular fragment of the sea urchin egg receptor for sperm.
Matsumoto et al. Structural study of the sugar chains of human lactoferrin: Finding of four novel complex-type asparagine-linked sugar chains
Cantin et al. DNA synthesis in cultured adult cardiocytes
Childs et al. Differences in carbohydrate moieties of high molecular weight glycoproteins of human lymphocytes of T and B origins revealed by monoclonal autoantibodies with anti-I and anti-i specificities
Samor et al. Preliminary results on the carbohydrate moiety of factor VIII/von Willebrand factor (FVIII/vWf)
Dahms et al. Lymphocyte function-associated antigen 1 (LFA-1) contains sulfated N-linked oligosaccharides.
Kalan et al. Action of rennin on κ-casein, the amino acid compositions of the para-κ-casein, and glycomacropeptide fractions
Hirabayashi A general comparison of two major families of animal lectins
Ettensohn et al. A new method for isolating primary mesenchyme cells of the sea urchin embryo: Panning on wheat germ agglutinin-coated dishes
Åkerström et al. α1‐Microglobulin Glycopeptides Inhibit Antigen‐Specific Stimulation of Human Peripheral Blood Leucocytes
EP1245575A3 (de) Funktionell aktive selektinderivierte Peptide und Ligand für GMP140
Tanji et al. The primary structure of the major pepsinogen from the gastric mucosa of tuna stomach
Bell et al. Effect of galactose oxidase, with and without prior sialidase treatment, on the viability of erythrocytes in circulation.
Murayama et al. Amino acid sequence of monkey erythrocyte glycophorin MK. Its amino acid sequence has a striking homology with that of human glycophorin A
WO2002022784A2 (en) Expression, preparation, uses, and sequence of recombinantly-derived soluble hla-g
Allen et al. NONDIALYZABLE SULFATED SIALOGLYCOPEPTIDE FRACTIONS DERIVED FROM BOVINE HEIFER BRAIN GLYCOPROTEINS. ISOLATION, CHARACTERIZATTON AND CARBOHYDRATE‐PEPTIDE LINKAGE STUDIES 1
Bezouška et al. Localization and characterization of the carbohydrate-binding site of the porcine lymphocyte mannan-binding protein

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee